[HTML][HTML] Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting
R Evans, GM Thurber - Scientific Reports, 2022 - nature.com
Abstract Antibody-Drug Conjugates (ADCs) have rapidly expanded in the clinic, with 7 new
approvals in 3 years. For solid tumors, high doses of ADCs improve tissue penetration and …
approvals in 3 years. For solid tumors, high doses of ADCs improve tissue penetration and …
Processing of antibodies bound to B‐cell lymphomas and lymphoblastoid cell lines
N Vangeepuram, GL Ong… - … International Journal of …, 1997 - Wiley Online Library
BACKGROUND Previous experiments demonstrated that some human B‐cell lymphoma
cell lines were unusual in that antibodies bound to the cell surface dissociated at high levels …
cell lines were unusual in that antibodies bound to the cell surface dissociated at high levels …
Alpha or beta emitters attached to fragments in radioimmunotherapy
DM Goldenberg, TM Behr - US Patent 6,667,024, 2003 - Google Patents
The present invention relates to radioimmunoconjugates useful in targeted
radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The …
radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The …
Accelerated clearance systems
SK Sharma - Advanced drug delivery reviews, 1996 - Elsevier
To optimise the therapeutic effects of the ADEPT approach and to avoid toxicity, it is
desirable to reduce plasma enzyme activity after tumour localisation has occured. High …
desirable to reduce plasma enzyme activity after tumour localisation has occured. High …
Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCγ-receptor-II-mediated mechanism and by drugs
SF Vervoordeldonk, AY Balkenende… - Cancer Immunology …, 1996 - Springer
Our aim is to treat patients with B cell malignancies with radioimmunotherapy using
monoclonal antibodies (mAb) such as CD19, CD20 and CD22. In this study we investigated …
monoclonal antibodies (mAb) such as CD19, CD20 and CD22. In this study we investigated …
Alpha or beta emitters attached to fragments in radioimmunotherapy
DM Goldenberg, TM Behr - US Patent 7,220,399, 2007 - Google Patents
The present invention relates to radioimmunoconjugates useful in targeted
radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The …
radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The …